Phlebogriffe – a new device for mechanochemical ablation of incompetent saphenous veins: a pilot study

Ciostek, Piotr; Kowalski, Marcin; Woźniak, W; Miłek, Tomasz; Myrcha, Piotr; Migda, Bartosz

doi:10.5114/pr.2015.57466

Cited by 18 publications

(26 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, our results are consistent with the preliminary results of other authors using this specific technique, however based on the smaller group of patients. Ciostek et al in their preliminary study, reported efficacy of the system reaching 94.9% after 3 months of follow-up [24].…”

Section: Discussionmentioning

confidence: 93%

Application of endovenous mechanochemical ablation (MOCA) with Flebogrif™ to treat varicose veins of the lower extremities: a single center experience over 3 months of observation

Zubilewicz

Terlecki

et al. 2017

Acta Angiologica

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 93%

Application of endovenous mechanochemical ablation (MOCA) with Flebogrif™ to treat varicose veins of the lower extremities: a single center experience over 3 months of observation

Zubilewicz

Terlecki

et al. 2017

Acta Angiologica

View full text Add to dashboard Cite

show abstract

“…z o.o. seems to be an interesting proposal, extending the possibilities of effective solution of the problem of GSV/SSV insufficiency, perfectly matching the definition of the minimally invasive procedure [5,6].…”

Section: Introductionmentioning

confidence: 80%

The novel minimally invasive mechano-chemical technique of the saphenous vein ablation. Our center experience: results of 24 months follow-up

et al. 2019

View full text Add to dashboard Cite

Introduction: The aim of the study was to evaluate the efficacy of the endovascular ablation method of GSV/ /SSV superficial venous insufficiency using Flebogrif ® catheter, the safety of the method, expressed in number and quality of observed complications in 24-month observation. Material and methods: Initially, the observed group included 200 patients undergoing ablation of insufficient GSV/SSV. During 24 months of observation, this number decreased to 158, which seems to be a natural process. All patients signed the informed consent form approved by the Bioethics Committee of the Medical University of Lublin. Based on clinical evaluation, including ultrasound assessment, 200 patients, including 170 women and 30 men, were admitted to the study using the adopted criteria of inclusion/exclusion. In the studied group of patients, 172 great saphenous veins (GSV) and 28 short saphenous veins (SSV) were ablated. The treated inefficient veins were punctured at three levels depending on the length of the segment of insufficient GSV/SSV. Each patient was treated with a compression agent in the form of a second compression class elastic stockings (20-30 mm Hg). Control visits on the basis of the accepted protocol were established in 1, 3, 6, 12, 24, 36 months after the procedure. Results: During 24 months of observation, the evaluation of the Flebogrif ® catheter method was based on the analysis of results obtained in four categories: effectiveness of the method, expressed as the ratio of the number of successfully closed veins ablated with the Flebogrif ® catheter to the number of observed cases of recanalization; clinical improvement of venous insufficiency symptoms, based on the VCSS, CEAP, VAPS scale; safety of the method, expressed in terms of quantity and quality of observed complications; technical characteristics of the method. The obtained results were analyzed statistically using tests for non-parametric variables. The effectiveness of the method based on the obtained results was 92%. A statistically significant decrease in the intensity of clinical symptoms in relation to the preoperative condition was observed. The number and quality of the observed complications allow considering the procedure of vein ablation with the use of Flebogrif ® catheter as safe, possible to perform in ambulatory conditions. Conclusions: Effectiveness of the method of 92% in 24-month observation; good cosmetic effect; a statistically significant decrease in the intensity of clinical symptoms in 24-month observation; the low incidence of complications allows to consider the method safe; the method of surgery allows to perform the procedure in ambulatory conditions.

show abstract

“…The ClariVein device (Vascular Insights, LLC, Quincy, MA, USA) is at the moment the most popular MOCA system [1,2]. Recently, the Flebogrif system (Balton, Warsaw, Poland) has also become commercially available [7]. Mechanochemical ablation with the ClariVein is gaining popularity among medical professionals and patients.…”

Section: One-year Results Of Fifty Consecutive Patients Treated With mentioning

confidence: 99%

One-year results of fifty consecutive patients treated with mechanochemical ablation of great and small saphenous vein

Stanišić¹,

Węgrzynowski²,

Pawlaczyk-Gabriel³

2015

View full text Add to dashboard Cite

102Mechanochemical ablation (MOCA) of the great saphenous vein (GSV) and small saphenous vein (SSV) is a relatively new method of treatment for superficial venous reflux [1][2][3]. This method is based on mechanical injury of the venous wall by rotating the tip of the catheter with subsequent injection of a sclerosant: polidocanol or sodium tetradecyl sulfate (STS). The method has been developed as an alternative to thermal ablation, such as endovenous laser ablation (EVLA), radiofrequency ablation or ablation with steam [4]. Recently, medical glues have provided a novel alternative to MOCA [5,6]. The rationale to introduce MOCA into medical practice is based on the potential risk of thermal injury of surrounding anatomic structures during EVLA or other methods of thermal ablation [4]. MOCA systems, which are cur- AbstrActObjectives: Mechanochemical ablation (MOCA) of the great saphenous vein (GSV) and the small saphenous vein (SSV) is an alternative to thermal ablation for the treatment of superficial venous reflux. The aim of this study was to assess the efficacy of MOCA for the treatment of incompetent GSV and SSV. Material and methods: We included 50 patients (60 legs) with incompetent GSV or SSV. Patients were aged 22-71 years, with median age of 41 years. Diameters of the saphenous veins treated were 4-16 mm, with median diameter 9 mm. Lengths of incompetent segments of the GSVs were 20-45 cm, with median length 36 cm. Lengths of incompetent segments of the SSVs were 12-25 cm, with median length 17 cm. We performed venous ablation using the ClariVein device with simultaneous injection of 2% polidocanol in the dose of 0.2 ml per cm of the treated vein. All patients completed 12 months follow-up. Results: In all patients the procedure resulted in complete occlusion of the incompetent segment of the saphenous vein. Additional foam sclerotherapy was needed in 41 legs (68.3%). After 12 months partial or complete recanalisation was revealed in one GSV and 3 SSVs. The remaining veins (93.3%) were completely occluded. During the procedure we observed transient signs of polidocanol toxicity in 2 patients. Conclusions: MOCA using the ClariVein device is a safe method for ablation of incompetent truncal veins in patients who prefer to be managed quickly, without pain and with satisfactory results after 1 year.

show abstract

Phlebogriffe – a new device for mechanochemical ablation of incompetent saphenous veins: a pilot study

Cited by 18 publications

References 9 publications

Application of endovenous mechanochemical ablation (MOCA) with Flebogrif™ to treat varicose veins of the lower extremities: a single center experience over 3 months of observation

Application of endovenous mechanochemical ablation (MOCA) with Flebogrif™ to treat varicose veins of the lower extremities: a single center experience over 3 months of observation

The novel minimally invasive mechano-chemical technique of the saphenous vein ablation. Our center experience: results of 24 months follow-up

One-year results of fifty consecutive patients treated with mechanochemical ablation of great and small saphenous vein

Contact Info

Product

Resources

About